•
Jun 30, 2021

AptarGroup Q2 2021 Earnings Report

AptarGroup's second quarter results for 2021 were reported.

Key Takeaways

AptarGroup reported a 16% increase in sales to $811 million, driven by strong core sales growth and positive currency effects. Core sales increased by 10%, with double-digit growth in Beauty + Home and Food + Beverage segments. Earnings per share were $0.81, and adjusted earnings per share were $0.91.

Reported sales grew 16% driven by strong core sales growth and positive currency effects.

Core sales increased 10% mainly on double digit core growth in Beauty + Home and Food + Beverage.

Reported earnings per share totaled $0.81, an increase of 29% compared to the prior year.

Adjusted EBITDA totaled $148 million, an increase of 8% compared to the prior year.

Total Revenue
$811M
Previous year: $699M
+16.0%
EPS
$0.91
Previous year: $0.8
+13.7%
Total Core Sales Growth
10%
Previous year: -6%
-266.7%
Beauty + Home Core Sales Growth
13%
Previous year: -13%
-200.0%
Pharma Core Sales Growth
2%
Previous year: 6%
-66.7%
Gross Profit
$288M
Previous year: $258M
+11.8%
Cash and Equivalents
$291M
Previous year: $248M
+17.7%
Free Cash Flow
$30.2M
Previous year: $81.3M
-62.8%
Total Assets
$4.11B
Previous year: $3.81B
+7.8%

AptarGroup

AptarGroup

AptarGroup Revenue by Segment

Forward Guidance

Aptar expects earnings per share for the third quarter of 2021, excluding any restructuring expenses, acquisition costs and changes in the fair value of equity investments, to be in the range of $0.90 to $0.98 and this guidance is based on an effective tax rate range of 28% to 30%.

Positive Outlook

  • Continued gradual improvement in Aptar’s beauty and beverage businesses as the reopening of economies is expected to continue at a measured pace
  • Ongoing steady demand for elastomer components for injection devices in the third quarter
  • Consolidated margins will improve as transition to a more balanced and steady growth pattern
  • Long-term views have not changed.
  • Fundamental growth story is intact across each of our markets.

Challenges Ahead

  • Broader macro factors impacting our business are not anticipated to change dramatically from what we experienced in the second quarter.
  • Uncertainties around the COVID-19 variants and limited resumption of intercontinental travel
  • Current inventory destocking cycle by our customers in the prescription drug market is expected to continue through the third quarter
  • Exceptionally strong custom tooling sales reported in the prior year third quarter by the Pharma segment’s active material science solutions division, is not expected to repeat.
  • Inflation and cost pressures continue to be a headwind, especially in raw material and transportation costs

Revenue & Expenses

Visualization of income flow from segment revenue to net income